HSBC/CALL/MODERNA/240/0.1/15.01.25 Stock

DE000HG807K3

Real-time Boerse Frankfurt Warrants 04:21:27 2024-06-07 EDT
0.76 ^EUR	0.00%

Current month	+58.33%
1 month	+280.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart MODERNA, INC.

Chart HSBC/CALL/MODERNA/240/0.1/15.01.25

Latest news about MODERNA, INC.

S&P 500, Nasdaq dip on the eve of US payrolls data	06-06	RE
Wall Street mixed as Nvidia retreat hits tech stocks; payrolls data in focus	06-06	RE
Transcript : Moderna, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 10:00 AM	06-06
Sector Update: Health Care Stocks Steady Premarket Thursday	06-06	MT

More news

Quotes 5-day view

Date	Price	Change
24-06-07	0.76	0.00%
24-06-06	0.76	+7.04%
24-06-05	0.71	+33.96%
24-06-04	0.53	-10.17%
24-06-03	0.59	+22.92%

Real-time Boerse Frankfurt Warrants

Last update June 07, 2024 at 04:21 am

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	MODERNA, INC.
Issuer	HSBC
WKN	HG807K
ISIN	DE000HG807K3
Date issued	2023-02-02
Strike	240 $
Maturity	2025-01-15 (223 Days)
Parity	10 : 1
Emission price	3.65 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	3.6 €
Lowest since issue	0.067 €
Spread	0.03 €
Spread %	3.66%

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Sector

More about the company